Acute myeloid leukemia (AML) continues to be an unmet clinical need for both adult and pediatric patients. Although CAR-T cell therapy has demonstrated substantial therapeutic potential, further advancements are necessary to achieve safe and lasting disease remission. In this webinar, CAR-CIK cell pioneer Dr. Sarah Tettamanti, from the Tettamnti foundation in Milan, Italy (alongside our Lead Product Manager, Shira Segal, at LUMICKS) discuss how Cell avidity was used to generate an additional layer of information to understand the mechanism of action and enhance decision-making on identifying the most efficacious candidates whilst limiting toxicity to healthy cells.
Learning objectives:
- Understand the mechanism of action of dual CAR-CIK cells using avidity measurements
- Dual CAR-CIK cells demonstrated reduced off-target toxicities whilst maintaining high specificity and avidity for CD123 and CD33 recognition on AML tumor targets
- Integrate avidity into your preclinical CAR characterization to improve decision-making in selecting the most efficacious candidate whilst minimizing off-target toxicity
